NIH RFA · NHLBI · R61, R33

RFA-HL-26-017: Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsNext due date: Oct 21, 2026Expires Dec 24, 2027

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
RFA-HL-26-017
Type
RFA
Activity code
R61R33
Primary institute
NHLBI · National Heart, Lung, and Blood Institute
Clinical trials
Not Allowed
Posted
Nov 22, 2024
Opens
Jan 11, 2025
Expires
Dec 24, 2027

RFA-HL-26-017 due dates

4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for RFA-HL-26-017
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 11, 2025February 11, 2025April 21, 2025July 2025October 2025December 2025
June 18, 2025June 18, 2025August 21, 2025November 2025January 2026April 2026
October 21, 2025October 21, 2025December 22, 2025March 2026May 2026July 2026
February 11, 2026February 11, 2026April 21, 2026July 2026October 2026December 2026
June 18, 2026June 18, 2026Not ApplicableNovember 2026January 2027April 2027
October 21, 2026October 21, 2026Not ApplicableMarch 2027May 2027July 2027
February 11, 2027February 11, 2027Not ApplicableJuly 2027October 2027December 2027
June 17, 2027June 17, 2027Not ApplicableNovember 2027January 2028April 2028
October 21, 2027October 21, 2027Not ApplicableMarch 2028May 2028July 2028

Projects funded under RFA-HL-26-017

NIH RePORTER lists 4 projects funded under RFA-HL-26-017 in FY2022–FY2026, with $2.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

4

Distinct projects, FY2022–FY2026

New awards

4

Type 1 (new project) award records

NIH funding

$2.4M

Award dollars under RFA-HL-26-017, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under RFA-HL-26-017
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY202654$2.4M

Institutions with the most funding

  1. Rice University$638K · 1 project
  2. Greenstone Biosciences, Inc.$626K · 1 project
  3. University of Arizona$563K · 1 project

Funding institutes

  • NHLBI$2.4M · 5

Activity codes funded

  • R615 records

What its predecessor RFA-HL-23-011 funded

RFA-HL-26-017 reissues RFA-HL-23-011. Its funding history is the best guide to who wins under this program: 26 projects and $21.5M in FY2022–FY2026.

Projects funded

26

Distinct projects, FY2022–FY2026

New awards

17

Type 1 (new project) award records

NIH funding

$21.5M

Award dollars under RFA-HL-23-011, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under RFA-HL-23-011
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202355$2.8M
FY202495$4.8M
FY2025157$7.7M
FY2026120$6.2M

Institutions with the most funding

  1. Emory University$1.6M · 2 projects
  2. Texas Heart Institute$1.6M · 2 projects
  3. University of South Florida$1.5M · 2 projects

Funding institutes

  • NHLBI$21.5M · 41

Activity codes funded

  • R6130 records
  • R3311 records

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under RFA-HL-26-017. Contact the program officer at the institute that fits your research before applying.

  • NHLBI · National Heart, Lung, and Blood Institute
  • NIAID · National Institute of Allergy and Infectious Diseases

Related notices

  1. Apr 28, 2026 · NOT-AI-26-002

    Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification R61/R33).

  2. Jan 28, 2026 · NOT-OD-26-029

    NIH Removing AIDS Application Due Dates from NOFOs.

  3. Mar 31, 2025 · NOT-OD-24-084

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…

  4. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  5. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Award terms

Application types allowed
NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Application budgets must not exceed direct costs of 400,000 per year during the R61 phase and also must not exceed direct costs of 400,000 per year during the R33 phase. The total budget Federal award and non-Federal matching contributions) should reflect the actual needs of the overall proposed project. Annual project budgets should reflect the actual costs anticipated in each year.Cost Matching…
Project period
The maximum project period of the combined R61 and R33 phases is 3 years, with up to 2 years for the R61 phase and up to 2 years for the R33 phase. The R61 and the R33 cannot be awarded in the same fiscal year. The scope of the proposed project should determine the requested project award period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications…
Funds available and number of awards
NHLBI intends to commit total costs of up to 4,466,000 in FY 2026, 4,466,000 in FY 2027, and 4,466,000 in FY 2028. NHLBI expects to fund up to 8 new awards in FY 2026, 8 new awards in FY 2027, and 8 new awards in FY 2028, for a total of up to 24 new awards for projects submitted to this NOFO and three companion funding opportunity announcements RFA-HL-26-018, RFA-HL-26-019, RFA-HL-26-020).The…

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

Other open NOFOs for R61, R33

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO